Cargando…

Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma

SIMPLE SUMMARY: Among other cancers, colorectal carcinoma (CRC) is one of the foremost causes of death worldwide. The mortality rate of those having CRC has increased dramatically in the past few years. Identification of novel regulatory molecules contributing to the progression of CRC remains a foc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Arun Pandian, Suresh, Bharathi, Sarodaya, Neha, Ko, Na-Re, Oh, Seung-Jun, Kim, Kye-Seong, Ramakrishna, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197902/
https://www.ncbi.nlm.nih.gov/pubmed/34072621
http://dx.doi.org/10.3390/cancers13112706
_version_ 1783707013012783104
author Chandrasekaran, Arun Pandian
Suresh, Bharathi
Sarodaya, Neha
Ko, Na-Re
Oh, Seung-Jun
Kim, Kye-Seong
Ramakrishna, Suresh
author_facet Chandrasekaran, Arun Pandian
Suresh, Bharathi
Sarodaya, Neha
Ko, Na-Re
Oh, Seung-Jun
Kim, Kye-Seong
Ramakrishna, Suresh
author_sort Chandrasekaran, Arun Pandian
collection PubMed
description SIMPLE SUMMARY: Among other cancers, colorectal carcinoma (CRC) is one of the foremost causes of death worldwide. The mortality rate of those having CRC has increased dramatically in the past few years. Identification of novel regulatory molecules contributing to the progression of CRC remains a focus of significant interest. The oncogenic role of USP29 has recently been explored in a few cancer types. However, evidence concerning the expression of USP29 in other cancers is currently lacking. We identified that USP29 is highly expressed in CRC and may contribute to the progression of CRC. Depletion of USP29 in HCT116 by CRISPR-Cas9 system reduced the growth of cancer cells. Furthermore, our data suggests that USP29 knockdown reduced the tumor volume of mouse xenograft models. Future investigations are required to validate the outcome of USP29-targted therapy in patients having CRC. ABSTRACT: Colorectal carcinoma is the third foremost cause of cancer-related deaths and accounts for 5.8% of all deaths globally. The molecular mechanisms of colon cancer progression and metastasis control are not well studied. Ubiquitin-specific protease 29 (USP29), a deubiquitinating enzyme, is involved in the occurrence and development of wide variety of cancers. However, its clinical significance and biological roles in colorectal carcinoma (CRC) remain unexplored. In this research, we observed that the rate of USP29 overexpression was higher in colon cancer patient tissues relative to its corresponding normal tissues. CRISPR-Cas9-mediated depletion of USP29 triggered DNA double strand breaks and delayed cell-cycle progression in HCT116 cells. We also demonstrated that USP29 depletion hampers the colony formation and increases apoptosis of HCT116 cells. USP29 knockdown significantly decreased CRC cell proliferation in vitro. Depletion of USP29 in HCT116 cells substantially reduced the tumor volume of mouse xenografts. In conclusion, our study shows that elevated expression of USP29 promotes malignancy in CRC, suggesting that USP29 could be a promising target for colon cancer therapy.
format Online
Article
Text
id pubmed-8197902
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81979022021-06-14 Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma Chandrasekaran, Arun Pandian Suresh, Bharathi Sarodaya, Neha Ko, Na-Re Oh, Seung-Jun Kim, Kye-Seong Ramakrishna, Suresh Cancers (Basel) Article SIMPLE SUMMARY: Among other cancers, colorectal carcinoma (CRC) is one of the foremost causes of death worldwide. The mortality rate of those having CRC has increased dramatically in the past few years. Identification of novel regulatory molecules contributing to the progression of CRC remains a focus of significant interest. The oncogenic role of USP29 has recently been explored in a few cancer types. However, evidence concerning the expression of USP29 in other cancers is currently lacking. We identified that USP29 is highly expressed in CRC and may contribute to the progression of CRC. Depletion of USP29 in HCT116 by CRISPR-Cas9 system reduced the growth of cancer cells. Furthermore, our data suggests that USP29 knockdown reduced the tumor volume of mouse xenograft models. Future investigations are required to validate the outcome of USP29-targted therapy in patients having CRC. ABSTRACT: Colorectal carcinoma is the third foremost cause of cancer-related deaths and accounts for 5.8% of all deaths globally. The molecular mechanisms of colon cancer progression and metastasis control are not well studied. Ubiquitin-specific protease 29 (USP29), a deubiquitinating enzyme, is involved in the occurrence and development of wide variety of cancers. However, its clinical significance and biological roles in colorectal carcinoma (CRC) remain unexplored. In this research, we observed that the rate of USP29 overexpression was higher in colon cancer patient tissues relative to its corresponding normal tissues. CRISPR-Cas9-mediated depletion of USP29 triggered DNA double strand breaks and delayed cell-cycle progression in HCT116 cells. We also demonstrated that USP29 depletion hampers the colony formation and increases apoptosis of HCT116 cells. USP29 knockdown significantly decreased CRC cell proliferation in vitro. Depletion of USP29 in HCT116 cells substantially reduced the tumor volume of mouse xenografts. In conclusion, our study shows that elevated expression of USP29 promotes malignancy in CRC, suggesting that USP29 could be a promising target for colon cancer therapy. MDPI 2021-05-31 /pmc/articles/PMC8197902/ /pubmed/34072621 http://dx.doi.org/10.3390/cancers13112706 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chandrasekaran, Arun Pandian
Suresh, Bharathi
Sarodaya, Neha
Ko, Na-Re
Oh, Seung-Jun
Kim, Kye-Seong
Ramakrishna, Suresh
Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
title Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
title_full Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
title_fullStr Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
title_full_unstemmed Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
title_short Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
title_sort ubiquitin specific protease 29 functions as an oncogene promoting tumorigenesis in colorectal carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197902/
https://www.ncbi.nlm.nih.gov/pubmed/34072621
http://dx.doi.org/10.3390/cancers13112706
work_keys_str_mv AT chandrasekaranarunpandian ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma
AT sureshbharathi ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma
AT sarodayaneha ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma
AT konare ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma
AT ohseungjun ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma
AT kimkyeseong ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma
AT ramakrishnasuresh ubiquitinspecificprotease29functionsasanoncogenepromotingtumorigenesisincolorectalcarcinoma